iBio, Inc. – AMEX:IBIO
iBio stock price today
$0.73
-1.72
-70.2%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 21 minutes
iBio stock price monthly change
+0.41%
month
iBio stock price quarterly change
+0.41%
quarter
iBio stock price yearly change
+72.53%
year
iBio key metrics
Market Cap | 21.60M |
Enterprise value | 11.87M |
P/E | -0.01 |
EV/Sales | 5.92 |
EV/EBITDA | -0.12 |
Price/Sales | 5.57 |
Price/Book | 0.59 |
PEG ratio | N/A |
EPS | -20.74 |
Revenue | N/A |
EBITDA | -29.74M |
Income | -53.67M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -5093.51% |
Oper. margin | -2359.13% |
Gross margin | 96.86% |
EBIT margin | -2359.13% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeiBio stock price history
iBio stock forecast
iBio financial statements
| Jun 2022 | 61K | -38.15M | -62555.74% |
|---|---|---|---|
| Mar 2023 | 0 | -6.31M | |
| Jun 2023 | 0 | -6.03M | |
| Mar 2024 | 0 | -3.17M |
| Oct 2025 | 0 | -1.59M | |
|---|---|---|---|
| Dec 2025 | 0 | -1.59M | |
| Mar 2026 | 0 | -1.59M | |
| Jul 2026 | 0 | -891.12K |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | 8.27% |
|---|---|
| 2021 | |
| 2022 | |
| 2023 | |
| 2024 |
| Dec 2022 | 51800000 | 32.97M | 63.66% |
|---|---|---|---|
| Mar 2023 | 44386000 | 26.99M | 60.82% |
| Jun 2023 | 41207000 | 25.82M | 62.67% |
| Mar 2024 | 50154000 | 25.29M | 50.43% |
| Jun 2022 | -11.50M | 477K | -10K |
|---|---|---|---|
| Mar 2023 | -3.87M | 8.24M | 1.46M |
| Jun 2023 | -4.97M | -6K | 2.74M |
| Mar 2024 | -3.65M | 1M | 5.02M |
iBio alternative data
| Aug 2023 | 105 |
|---|---|
| Sep 2023 | 105 |
| Oct 2023 | 105 |
| Nov 2023 | 26 |
| Dec 2023 | 26 |
| Jan 2024 | 26 |
| Feb 2024 | 26 |
| Mar 2024 | 26 |
| Apr 2024 | 26 |
| May 2024 | 26 |
| Jun 2024 | 26 |
| Jul 2024 | 26 |
iBio other data
4.41%
-95.59%
of IBIO is owned by hedge funds
13
-22
432.89K
-1.87M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 0 | 3976 |
| Mar 2023 | 0 | 5213 |
| Apr 2023 | 0 | 4382 |
| May 2023 | 0 | 4182 |
| Jun 2023 | 0 | 4184 |
| Jul 2023 | 0 | 51535 |
| Aug 2023 | 0 | 5011 |
| Oct 2023 | 0 | 9482 |
| Nov 2023 | 0 | 4881 |
| Patent |
|---|
Application Filling date: 11 Mar 2021 Issue date: 16 Sep 2021 |
Application Filling date: 9 Nov 2020 Issue date: 15 Apr 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2022 27 Sep 2022 | Q4 2022 Earnings Call Transcript |
| Q3 2022 12 May 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 14 Feb 2022 | Q2 2022 Earnings Call Transcript |
| Q4 2021 27 Sep 2021 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Thomas F. Isett III (1965) Chief Executive Officer, Pres & Chairman | $1,300,000 |
| Mr. Randy Joe Maddux (1961) Chief Operating Officer | $485,200 |
Dr. Martin B. Brenner D.V.M., Ph.D. (1972) Chief Scientific Officer | $375,950 |
Mr. Robert B. Kay (1940) Interim Sec. & Interim Treasurer | $150,000 |
-
What's the price of iBio stock today?
One share of iBio stock can currently be purchased for approximately $0.73.
-
When is iBio's next earnings date?
Unfortunately, iBio's (IBIO) next earnings date is currently unknown.
-
Does iBio pay dividends?
No, iBio does not pay dividends.
-
How much money does iBio make?
iBio has a market capitalization of 21.60M.
-
What is iBio's stock symbol?
iBio, Inc. is traded on the AMEX under the ticker symbol "IBIO".
-
What is iBio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of iBio?
Shares of iBio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are iBio's key executives?
iBio's management team includes the following people:
- Mr. Thomas F. Isett III Chief Executive Officer, Pres & Chairman(age: 60, pay: $1,300,000)
- Mr. Randy Joe Maddux Chief Operating Officer(age: 64, pay: $485,200)
- Dr. Martin B. Brenner D.V.M., Ph.D. Chief Scientific Officer(age: 53, pay: $375,950)
- Mr. Robert B. Kay Interim Sec. & Interim Treasurer(age: 85, pay: $150,000)
-
How many employees does iBio have?
As Jul 2024, iBio employs 26 workers.
-
When iBio went public?
iBio, Inc. is publicly traded company for more then 17 years since IPO on 19 Aug 2008.
-
What is iBio's official website?
The official website for iBio is ibioinc.com.
-
Where are iBio's headquarters?
iBio is headquartered at 8800 HSC Parkway, Bryan, TX.
-
How can i contact iBio?
iBio's mailing address is 8800 HSC Parkway, Bryan, TX and company can be reached via phone at +979 4460027.
iBio company profile:
iBio, Inc.
ibioinc.comExchange:
AMEX
Full time employees:
16
Industry:
Biotechnology
Sector:
Healthcare
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
8800 HSC Parkway
Bryan, TX 77807
Bryan, TX 77807
CIK: 0001420720
ISIN: US4510337086
CUSIP: 451033203
